Recently, line 3, 203 workshop of YaoPharma’s Shuitu manufacturing site (large international and industrial manufacturing base) passed 2010 GMP site inspection of China. Now, the manufacturing capacity of Yaopharma’s lyophilized formulations increased by 50%, which makes YaoPharma the largest manufacturer of lyophilized formulations.

During May 9 to 12, 2017, the inspection team from GMP certification center of Chongqing Food and Drug Administration conducted a 4-day inspection of line 3, 203 workshop of YaoPharma’s Shuitu manufacturing site (large international and industrial manufacturing base). After thorough inspection of both the hardware and software, the inspection team announced that the manufacturing line passed the GMP site inspection.

Passing 2010 GMP site inspection makes the manufacturing capacity of Shuitu new manufacturing site for lyophilized formulations increased by 50%, which greatly satisfy the market demand. It also marks that the manufacturing scale of Shuitu manufacturing site has topped the country ranking and YaoPharma’s capacity for lyophilized formulations continues to be number one in China.